Factory 99% Selumetinib CAS 606143-52-6 Effect on Peritoneal Cancer Selumetinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A294
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Selumetinib
• CAS: 606143-52-6
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 100g
• Function: Effect on Peritoneal Cancer
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Selumetinib
Appearance	White Powder
CAS NO.	606143-52-6
Molecular Formula	C17H15BrClFN4O3
Storage	Keep in a cool, dry, dark location

 

Selumetinib, also known as AZD6244, is a second-generation, selective, potent, and non-ATP competitive allosteric inhibitor of mitogen-activated protein/signal-regulated kinase kinase (MEK) 1/2. It specifically targets and inhibits the activity of MEK1/2, which are key enzymes in the MAPK/ERK signaling pathway.

 

 

1. Cancer Research: Selumetinib is extensively used in cancer research to investigate its potential therapeutic effects on various solid tumors, such as colorectal cancer, lung cancer, and melanoma.
2. Clinical Trials: It is currently being evaluated in clinical trials for the treatment of multiple human malignancies, particularly those with KRAS mutations.
3. Pharmaceutical Development: Selumetinib serves as a lead compound in the development of new pharmaceuticals targeting the MAPK/ERK signaling pathway.

1. Inhibition of MEK1/2: Selumetinib selectively inhibits the activity of MEK1/2, thereby blocking the downstream signaling of the MAPK/ERK pathway. This inhibition leads to the suppression of cell proliferation and the induction of apoptosis in cancer cells.
2. Antiproliferative Effects: By inhibiting MEK1/2, Selumetinib causes a time- and dose-dependent reduction in DNA synthesis and cell viability, resulting in growth arrest and apoptosis in cancer cell lines.
3. Combination Therapy: Selumetinib has been explored in combination with other therapeutic agents for the treatment of refractory cancers, demonstrating synergistic effects in preclinical studies.